Cargando…

Interleukin-24 therapy- a potential new strategy against liver fibrosis

Detalles Bibliográficos
Autores principales:	Petrescu, Anca D., DeMorrow, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921474/ https://www.ncbi.nlm.nih.gov/pubmed/33639397 http://dx.doi.org/10.1016/j.ebiom.2021.103245

Ejemplares similares

Targeting Certain Interleukins as Novel Treatment Options for Liver Fibrosis
por: An, Su Yeon, et al.
Publicado: (2021)

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
por: Petrescu, Anca D., et al.
Publicado: (2021)

Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease
por: Petrescu, Anca D., et al.
Publicado: (2018)

Glucocorticoids Cause Gender-Dependent Reversal of Hepatic Fibrosis in the MDR2-Knockout Mouse Model
por: Petrescu, Anca D., et al.
Publicado: (2017)

Ghrelin reverses ductular reaction and hepatic fibrosis in a rodent model of cholestasis
por: Petrescu, Anca D., et al.
Publicado: (2020)

Gulf war illness-related chemicals increase CD11b/c(+) monocyte infiltration into the liver and aggravate hepatic cholestasis in a rodent model
por: Petrescu, Anca D., et al.
Publicado: (2018)

Elevated circulating TGFβ1 during acute liver failure activates TGFβR2 on cortical neurons and exacerbates neuroinflammation and hepatic encephalopathy in mice
por: McMillin, Matthew, et al.
Publicado: (2019)

Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy
por: Widjaja, Anissa A., et al.
Publicado: (2020)

Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management
por: Leyva-Illades, Dinorah, et al.
Publicado: (2013)

Role of the Hypothalamic–Pituitary–Adrenal Axis in Health and Disease
por: DeMorrow, Sharon
Publicado: (2018)

FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy
por: McMillin, Matthew, et al.
Publicado: (2018)

Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice
por: McMillin, Matthew, et al.
Publicado: (2017)

Bile Acid Signaling in Neurodegenerative and Neurological Disorders
por: Grant, Stephanie M., et al.
Publicado: (2020)

Interleukin-24 protects against liver injury in mouse models
por: Wang, Hsiao-Hsuan, et al.
Publicado: (2021)

Recent advances in hepatic encephalopathy
por: Liere, Victoria, et al.
Publicado: (2017)

A Breathe in Cystic Fibrosis Therapy: A New Therapeutic Endeavor for Cysteamine
por: De Stefano, Daniela, et al.
Publicado: (2015)

The Direct Contribution of Astrocytes and Microglia to the Pathogenesis of Hepatic Encephalopathy
por: Jaeger, Victoria, et al.
Publicado: (2019)

Fighting liver fibrosis to reduce mortality associated with chronic liver diseases: The importance of new molecular targets and biomarkers
por: Muriel, Pablo
Publicado: (2019)

The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review
por: Özkan, Alican, et al.
Publicado: (2020)

Why Is Hormone Therapy Successful Strategy Against Coronavirus-19?
por: Asadikaram, Gholamreza, et al.
Publicado: (2021)

Interleukin-27: a potential new sepsis biomarker exposed through genome-wide transcriptional profiling
por: Scicluna, Brendon P, et al.
Publicado: (2012)

Targeting mPGES-1 as a New Strategy against Neuroblastoma
por: Comunanza, Valentina
Publicado: (2018)

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
por: Andersen, Mads Hald, et al.
Publicado: (2006)

Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents
por: Frampton, Gabriel, et al.
Publicado: (2010)

Interleukin-12, Dendritic Cells, and the Initiation of Host-protective Mechanisms against Toxoplasma gondii
por: Johnson, Lawrence L., et al.
Publicado: (1997)

Regenerative Potential of Mesenchymal Stem Cells’ (MSCs) Secretome for Liver Fibrosis Therapies
por: Nazarie (Ignat), Simona-Rebeca, et al.
Publicado: (2021)

Taking stock of gene therapy for cystic fibrosis
por: Stern, Myra, et al.
Publicado: (2000)

A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies
por: Bévant, Kevin, et al.
Publicado: (2020)

New potential targeted strategies in small cell lung cancer
por: de Toro, María, et al.
Publicado: (2023)

Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now
por: Lee, Chi Ho, et al.
Publicado: (2022)

Modulation of Liver Inflammation and Fibrosis by Interleukin-37
por: Mountford, Steffeni, et al.
Publicado: (2021)

The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections
por: Junkins, Robert D, et al.
Publicado: (2014)

A new direction in the pathogenesis of idiopathic pulmonary fibrosis?
por: Gauldie, Jack, et al.
Publicado: (2002)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

The Pleiotropic Functions of Interleukin 15: Not so Interleukin 2–Like after All
por: Ma, Averil, et al.
Publicado: (2000)

Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases
por: Waldmann, Thomas A
Publicado: (2004)

Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease
por: Rackayová, Veronika, et al.
Publicado: (2021)

The Janus-like Face of IL-4Rα in Macrophages during Liver Fibrosis
por: Ritz, Thomas, et al.
Publicado: (2018)

Dioscin: A new potential inhibitor of Skp2 for cancer therapy
por: Jiang, Wenxiao, et al.
Publicado: (2020)

Screening for mutations in human cardiomyopathy- is RBM24 a new but rare disease gene?
por: Gaertner, Anna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4g0fb0ed876nee8s2tki076qt8